Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death

Trial Profile

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Celivarone (Primary) ; Amiodarone
  • Indications Sudden death; Ventricular fibrillation; Ventricular tachycardia
  • Focus Therapeutic Use
  • Acronyms ALPHEE
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Nov 2011 Preliminary results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 14 Nov 2011 Results published in the Circulation.
    • 22 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top